Key result
Atrial refractoriness emerges as a potential electrical biomarker to indicate substrate severity and predict AF outcomes.
Why the study?
Patients with the same atrial fibrillation subtype can differ in symptom severity, substrate severity, and treatment response, creating a need for an electrical biomarker of the underlying substrate to guide patient-tailored therapy.
Can atrial refractoriness be used as an electrical biomarker for staging the arrhythmogenic substrate underlying atrial fibrillation?
Can atrial refractoriness be used as an electrical biomarker for staging the arrhythmogenic substrate underlying atrial fibrillation?
This review explores the potential of using atrial refractoriness as an electrical biomarker to stage the arrhythmogenic substrate in atrial fibrillation and guide patient-tailored therapy.
Atrial refractoriness merits further study as AF biomarker; leaves open its utility for substrate staging and therapy guidance.
Patients diagnosed with the same subtype of atrial fibrillation according to our current classification system may differ in symptom severity, severity of the arrhythmogenic substrate, and response to antiarrhythmic therapy. Hence, there is a need for an electrical biomarker as an indicator of the arrhythmogenic substrate underlying atrial fibrillation enabling patient-tailored therapy. The aim of this review is to investigate whether atrial refractoriness, a well-known electrophysiological parameter that is affected by electrical remodeling, can be used as an electrical biomarker of the arrhythmogenic substrate underlying atrial fibrillation. We discuss methodologies of atrial effective refractory period assessment, identify which changes in refractoriness-related parameters reflect different degrees of electrical remodeling, and explore whether these parameters can be used to predict clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Staveren et al. (2020) conducted a review in Atrial Fibrillation. Atrial refractoriness assessment was evaluated. Atrial refractoriness is explored as a potential electrical biomarker to indicate the severity of the arrhythmogenic substrate and predict clinical outcomes in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: